PFE Stock Recent News

The shares of Pfizer Inc (NYSE:PFE) were last seen up 4.9% to trade at $24.4, after the pharmaceutical giant's second-quarter results beat expectations.

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Pfizer (NYSE: PFE) has recently reported impressive second-quarter results, with both revenue and earnings exceeding analyst expectations. The company disclosed adjusted earnings of $0.78 per share on $14.65 billion in revenue, surpassing consensus estimates of $0.58 per share and $13.56 billion.

Pfizer Inc (NYSE:PFE, ETR:PFE) raised its full-year profit outlook on Tuesday after posting better-than-expected second-quarter earnings, driven by strong sales of key drugs including Comirnaty and Paxlovid. The drugmaker reported adjusted earnings of $0.78 per share, beating analysts' average estimate of $0.58, according to LSEG data.

Pfizer stock (PFE: NYSE) surged on Tuesday after the company delivered stronger-than-expected second-quarter results and lifted its profit outlook for the year. Revenue climbed 10% to $14.7 billion, topping Wall Street forecasts and offering a sign that Pfizer's core business is stabilising following a post-COVID slowdown.

Pfizer (PFE) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.6 per share a year ago.

Pfizer raises 2025 profit forecast after strong Q2 results, while Yum Brands struggles with weak US sales at KFC and Pizza Hut. Full earnings breakdown inside.

U.S. drugmaker Pfizer raised its full-year profit forecast on Tuesday after reporting better-than-expected results for the second quarter, boosted by strong demand for its heart disease drug, Vyndaqel, and blood thinner, Eliquis.

Pfizer hiked its full-year adjusted profit guidance on its cost cuts and strong business performance this year. The company also reported second-quarter results that topped Wall Street's estimates for the period.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2025 and reaffirmed its 2025 Revenue guidance while raising guidance(1) for Adjusted(2) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company.